Last updated: February 20, 2026
What is the drug associated with NDC 70000-0641?
NDC 70000-0641 is designated for Glyxambi (empagliflozin and linagliptin), primarily prescribed for type 2 diabetes mellitus. It combines an SGLT2 inhibitor with a DPP-4 inhibitor.
Market landscape overview
Glyxambi operates within a highly competitive diabetes medication market. The primary competitors include:
- Jardiance (empagliflozin) alone
- Jardiance and other SGLT2 inhibitors
- Tradjenta (linagliptin) alone
- Combos like Janumet (sitagliptin and metformin)
Major market players dominate with established brands, but combination drugs like Glyxambi cater to patients requiring dual therapy, providing convenience and improved adherence.
Market size and sales
- The global diabetes drugs market exceeded $84 billion USD in 2022.
- The market for SGLT2 and DPP-4 inhibitors specific to combination therapies is growing at a compound annual growth rate (CAGR) of approximately 15% (Frost & Sullivan, 2023).
- Glyxambi's U.S. sales approached $300 million USD in 2022; globally, sales are expanding in European and Asian markets.
Market share and adoption
- Glyxambi accounts for roughly 4-6% of the DPP-4 and SGLT2 combination segment.
- Adoption rates are influenced by prescriber familiarity and insurance reimbursement policies.
- The drug is approved for use in adult populations with type 2 diabetes mellitus as an adjunct to diet and exercise.
Regulatory and patent environment
- Glyxambi received FDA approval in 2017.
- The primary patents extending to 2027 restrict generic competition in the U.S.
- Patent litigation and patent extensions could influence market exclusivity timelines.
Price analysis and projections
Current list prices
- The wholesale acquisition cost (WAC) for Glyxambi averages $450 to $550 USD per month per supply (IQVIA, 2023).
- Insurance coverages and discounts reduce out-of-pocket costs for insured patients.
Pricing trends and potential shifts
- The drug's price has remained relatively stable over the past 3 years, with minor adjustments for inflation and market factors.
- Entry of generic versions post-patent expiration (anticipated 2027) could reduce prices by 50-70%, aligning with historical patterns for similar drugs.
Price projection for the next 5 years
| Year |
Estimated Average Wholesale Price (USD) per month |
Assumptions |
| 2023 |
\$500 |
Current market conditions |
| 2024 |
\$510 |
Slight inflation and demand growth |
| 2025 |
\$520 |
Continued demand, no market disruption |
| 2026 |
\$530 |
Pre-patent expiry, partial price stabilization |
| 2027 |
\$250 - \$300 |
Post-patent expiry, generic entry begins |
Note: Prices likely to decline sharply after patent expiry due to competition.
Future market trajectory considerations
- The expanding role of combination therapies in diabetes management supports sustained demand.
- Patent expirations will introduce generic options, exerting downward pressure on prices.
- Reimbursement and formulary decisions by payers will influence real-world prices.
Key factors influencing market and prices
- Regulatory approvals for new formulations or indications.
- Competitive entrants offering cheaper generics.
- payer policies favoring cost-effective treatments.
- Patient adherence driven by pricing and drug convenience.
- Research trends favoring triple combination therapies.
Key Takeaways
- Glyxambi's market is growing but constrained by patent exclusivity until 2027.
- Current U.S. list prices hover around $500 per month, with discounts lowering patient costs.
- Post-patent expiration in 2027, prices could fall by half or more due to generics.
- The therapy's role in managing complex diabetes cases sustains demand despite pricing pressures.
- Market expansion in Europe and Asia contributes to global sales forecasts.
FAQs
1. What factors could accelerate patent challenges for Glyxambi?
Patent litigation, regulatory disputes, or new evidence showing patent invalidity can shorten exclusivity periods, potentially leading to earlier generic entry.
2. How does Glyxambi compare in efficacy to monotherapies?
Combination therapy like Glyxambi offers improved glycemic control compared to monotherapies by targeting multiple pathways, shown in clinical trials to reduce HbA1c levels more effectively.
3. What is the likelihood of significant price drops before patent expiry?
Unlikely. Price reductions are typically associated with patent expiration and market entry of generics. Early biosimilar or alternative therapies could influence prices but are less common in small molecule drugs.
4. How are insurance policies affecting Glyxambi’s market penetration?
Coverage decisions vary, impacting patient access and reimbursement rates. High out-of-pocket costs can limit use despite clinical effectiveness.
5. Are there ongoing clinical trials that could impact Glyxambi’s market?
Yes, studies are examining additional indications and combination approaches, which could extend its utility or influence pricing strategies.
References
[1] Frost & Sullivan. (2023). Global Diabetes Medications Market Report.
[2] IQVIA. (2023). National Prescription Audit Data.
[3] U.S. Food and Drug Administration. (2017). FDA Approval of Glyxambi.
